Clinical Study on the Safety and Efficacy of Umbilical Cord Blood Infusion in Treating Bone Marrow Suppression .

Prior treatment

• 2)Presence of interstitial lung disease, non-infectious pneumonia, or uncontrolled systemic diseases (such as diabetes, hypertension, pulmonary fibrosis, and acute pneumonia, etc.). Any unstable systemic diseases: including but not limited to unstable angina, cerebrovascular accident or transient ischemic attack (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association NYHA classification ≥ III,), severe arrhythmias requiring medication, liver, kidney, or metabolic diseases.
• 4\) Concurrent diagnosis of malignant tumors in other organs;
• 5\) Concurrent diagnosis of other hematological disorders;

Other illness

• 3\) Any other uncontrolled active diseases that may interfere with participation in the trial;

Lab values

• 1\) Other factors that may cause abnormalities in white blood cells and neutrophils, such as concurrent infections, invasive procedures, etc.

Other

• 6\) Inability to understand or comply with the study protocol;
• 7\) Individuals deemed unsuitable for participation in this trial by the investigator.

• 1\) Ages 60-80 years , gender unlimited;
• 2\) Patients clinically diagnosed with MDS or AML;
• 3\) Completed chemotherapy and clinically diagnosed with bone marrow suppression grade 2 or above;
• 4\) Patients with no severe impairment of liver and kidney function (total bilirubin (TBIL): ≤ 1.5×ULN; ALT or AST: ≤ 2.5×ULN; Alkaline phosphatase: ≤ 3×ULN; Serum creatinine: ≤ 1.5×ULN);
• 5\) Normal cardiac function;
• 6\) Patients with ECOG 0-2;
• 7\) Patients or their families have been informed and voluntarily signed a written informed consent form.